PATH | VRL
Menu

Impact of MenAfriVac in Nine Countries of the African Meningitis Belt, 2010–15: An Analysis of Surveillance Data

This article, published in The Lancet Infectious Diseases, analyzes surveillance data from nine countries on suspected and confirmed cases of meningitis to quantify the impact of MenAfriVac®, a meningococcal group A conjugate vaccine. The authors found that the incidence of suspected meningitis cases declined by 57 percent in vaccinated compared with unvaccinated populations, and in fully vaccinated populations, the incidence of confirmed group A disease was reduced by more than 99 percent. They conclude that MenAfriVac introduction has led to substantial reductions in the incidence of suspected meningitis and epidemic risk, and a substantial effect on confirmed group A meningococcal meningitis.

Author: Trotter CL, Lingani C, Fernandez K, et al.

Published: 2017

» Visit web page (English)

(Located at www.thelancet.com)

Citation: Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in Nine Countries of the African Meningitis Belt, 2010–15: An Analysis of Surveillance Data. The Lancet Infectious Diseases. 2017;17(8):867-872.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa